V 2023

DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023

DEMLOVÁ, Regina and Michaela KUBELOVÁ

Basic information

Original name

DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023

Name in Czech

DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023

Authors

DEMLOVÁ, Regina (203 Czech Republic, guarantor) and Michaela KUBELOVÁ (203 Czech Republic, belonging to the institution)

Edition

NA. Brno, 16 pp. NA, 2023

Publisher

MU LF/MŠMT/MOÚ

Other information

Language

English

Type of outcome

Výzkumná zpráva

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14110/23:00133170

Organization unit

Faculty of Medicine

Keywords (in Czech)

metastatický kolorektální karcinom; wild-type KRAS / NRAS; miR-31-5p; RASmiR; klinická studie

Keywords in English

metastatic colorectal cancer; wild-type KRAS / NRAS; miR-31-5p; RASmiR; clinical study

Tags

Změněno: 23/1/2024 13:41, Bc. Hana Vladíková, BBA

Abstract

V originále

Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) Phase II. This is the fourth annual DSUR for the RASmiR trial summarising safety data received by the Sponsor from August 1, 2022 – July 31, 2023. Clinical trial RASmiR is a multicenter, open label, single-arm, phase II trial. During the period under review, 30 patients were enrolled to the study.

Links

90249, large research infrastructures
Name: CZECRIN IV